Magenta Therapeutics, Inc. (MGTA)

Market Cap	83.04M
Revenue (ttm)	n/a
Net Income (ttm)	-76.94M
Shares Out	58.89M
EPS (ttm)	-1.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,013
Open	1.37
Previous Close	1.40
Day's Range	1.34 - 1.48
52-Week Range	0.92 - 8.49
Beta	2.08
Analysts	Buy
Price Target	5.10 (+261.7%)
Earnings Date	Nov 2, 2022

About MGTA

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that cause acute myeloid leukemia and myelodysplastic syndromes, which is under Phase I/II clinical trial; CD45-antibody drug conjugate that targets HSCs and immune cells, which is in investigational new drug a...

• Industry: Biotechnology
• Founded: 2015
• CEO: Jason Gardner
• Employees: 70
• Stock Exchange: NASDAQ
• Ticker Symbol: MGTA

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for MGTA stock is "Buy." The 12-month stock price forecast is 5.1, which is an increase of 261.70% from the latest price.

Price Target

$5.1

(261.70% upside)

Analyst Consensus: Buy

Stock Forecasts